NASDAQ$TRVN
Trevena Inc · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
Trevena reported financial results for Q4 2019 and provided an overview of its 2019 and 2020 year-to-date operational highlights.
Trevena reported a net loss attributable to common stockholders of $6.4 million, or $0.07 per share, for the fourth quarter of 2019. The company's cash, cash equivalents, and marketable securities were $35.8 million at December 31, 2019.
- FDA acknowledged receipt of the resubmitted NDA for IV Oliceridine with a PDUFA goal date set for August 7, 2020.
- Initiated proof-of-concept studies for acute migraine (TRV250) and opioid use disorder (TRV734).
- Announced NIH collaboration to evaluate TRV045 for epilepsy.
- Updated guidance on extended cash runway, funding operations into Q1 2021.
Headline financials
Revenue & EPS history
Trevena · Revenue · Quarterly
$31K
Revenue by segment
Trevena · $69K total across 1 segment · Q4 2020
- Product Revenue$69K—100.0%
Forward guidance
Trevena believes that its cash and cash equivalents and marketable securities as of December 31, 2019, together with interest thereon, to be sufficient to fund the Company’s operating expenses and capital expenditure requirements into the first quarter of 2021.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2019
-2.3%
Avg return
Earnings day
-1.7%
Avg return
5 days after
-10.7%
Avg return
30 days after
44%
20 / 45 earnings
Positive
+15.1%
Q2 2020
Best reaction
-43.9%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2024 | +9.3% | +12.2% | -5.1% | |
| Q2 2024 | -16.0% | +6.2% | +32.5% | |
| Q1 2024 | -19.4% | -9.3% | -16.5% | |
| Q4 2023 | -19.4% | -9.3% | -16.5% | |
| Q4 2025 | +0.0% | -9.3% | -16.5% | |
| Q3 2023 | -1.5% | -3.2% | +1.0% | |
| Q2 2023 | +3.1% | +3.4% | -20.9% | |
| Q1 2023 | +2.9% | +14.1% | -7.4% | |
| Q4 2022 | -4.1% | +0.4% | -11.2% | |
| Q3 2022 | -43.9% | -33.0% | -50.0% | |
| Q2 2022 | +6.3% | +5.0% | -12.9% | |
| Q4 2021 | +13.8% | +4.1% | -32.7% | |
| Q1 2022 | +13.8% | +4.1% | -32.7% | |
| Q3 2021 | -17.1% | -21.2% | -25.9% | |
| Q2 2021 | -8.6% | -15.0% | -10.7% | |
| Q1 2021 | +2.8% | +3.9% | -5.0% | |
| Q4 2020 | -5.9% | +5.4% | -12.2% | |
| Q3 2020 | -6.5% | -8.8% | -8.4% | |
| Q2 2020 | +15.1% | -2.1% | -26.9% | |
| Q1 2020 | +4.0% | +21.0% | +45.4% | |
| Q4 2019 | -5.7% | -14.4% | -41.4% | |
| Q3 2019 | -20.4% | -23.9% | -32.1% | |
| Q2 2019 | +3.3% | +0.5% | -1.1% | |
| Q1 2019 | -9.0% | -13.5% | -32.3% | |
| Q4 2018 | -0.7% | +13.6% | +3.4% | |
| Q3 2018 | +7.2% | +10.0% | +2.6% | |
| Q2 2018 | +10.1% | +8.8% | +21.6% | |
| Q1 2018 | +8.2% | -3.4% | -13.0% | |
| Q4 2017 | +2.0% | -5.0% | -19.3% | |
| Q3 2017 | -2.7% | +18.7% | -4.7% | |
| Q2 2017 | -2.8% | -2.0% | -4.0% | |
| Q1 2017 | -4.1% | -6.2% | -24.8% | |
| Q4 2016 | -8.3% | -3.5% | -17.0% | |
| Q3 2016 | -8.3% | -8.8% | +19.1% | |
| Q2 2016 | +0.1% | +2.5% | -0.1% | |
| Q1 2016 | +3.3% | — | — | |
| Q4 2015 | -13.9% | — | — | |
| Q3 2015 | +1.5% | — | — | |
| Q2 2015 | +6.7% | — | — | |
| Q1 2015 | +0.0% | — | — | |
| Q4 2014 | +8.5% | — | — | |
| Q3 2014 | -0.9% | — | — | |
| Q2 2014 | +0.5% | — | — | |
| Q1 2014 | -1.7% | — | — | |
| Q4 2013 | -7.0% | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro